Payment overview · 2025
General Payments
$45.31
2 reported records · 2 companies
Healthcare provider profile · identity verified
Roberto Javier Ruiz, M.D.
Allopathic & Osteopathic Physicians|General Practice · SAN ANTONIO, TX · NPI 1699753426
Verified facts
What the public records show
CMS Open Payments records show Roberto Javier Ruiz, M.D. received $45.31 in general payments during 2025 across 2 reported records.
Abbott Laboratories accounted for 65.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.60 | 65.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.71 | 34.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.31 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 616 | 215 |
| Lisinopril | Lisinopril | 360 | 122 |
| Metformin Hcl | Metformin Hcl | 270 | 90 |
| Losartan Potassium | Losartan Potassium | 255 | 92 |
| Alprazolam | Alprazolam | 253 | 38 |
| Gabapentin | Gabapentin | 225 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 79 |
| Tramadol Hcl | Tramadol Hcl | 200 | 55 |
| Metformin Hcl Er | Metformin Hcl | 186 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 27 |
| Mounjaro | Tirzepatide | 166 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 48 |
| Omeprazole | Omeprazole | 142 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 36 |
| Montelukast Sodium | Montelukast Sodium | 123 | 44 |
| Glipizide | Glipizide | 119 | 38 |
| Glimepiride | Glimepiride | 116 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 35 |
| Simvastatin | Simvastatin | 95 | 32 |
| Trulicity | Dulaglutide | 92 | 26 |
| Baclofen | Baclofen | 91 | 25 |
| Prednisone | Prednisone | 91 | 72 |
| Famotidine | Famotidine | 87 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 32 |
| Ibuprofen | Ibuprofen | 80 | 36 |
| Jardiance | Empagliflozin | 80 | 32 |
| Telmisartan | Telmisartan | 76 | 27 |
| Spironolactone | Spironolactone | 75 | 26 |
| Trazodone Hcl | Trazodone Hcl | 75 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 29 |
| Clonazepam | Clonazepam | 70 | 19 |
| Furosemide | Furosemide | 70 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 24 |
| Sertraline Hcl | Sertraline Hcl | 69 | 28 |
| Carvedilol | Carvedilol | 67 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 64 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 21 |
| Januvia | Sitagliptin Phosphate | 62 | 23 |
| Ozempic | Semaglutide | 60 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 46 |
| Enalapril Maleate | Enalapril Maleate | 53 | 16 |
| Mupirocin | Mupirocin | 53 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Cephalexin | Cephalexin | 50 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 16 |
| Lorazepam | Lorazepam | 44 | 13 |
| Myrbetriq | Mirabegron | 44 | 16 |
| Allopurinol | Allopurinol | 43 | 16 |
| Ezetimibe | Ezetimibe | 39 | 14 |
| Amoxicillin | Amoxicillin | 37 | 35 |
| Azithromycin | Azithromycin | 35 | 33 |
| Diazepam | Diazepam | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | 15 |
| Ondansetron Odt | Ondansetron | 34 | 15 |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | 11 |
| Pregabalin | Pregabalin | 25 | 12 |
| Hydrocortisone | Hydrocortisone | 24 | 14 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Fluconazole | Fluconazole | 22 | 14 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | 15 |
| Naproxen | Naproxen | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | 11 |
| Linzess | Linaclotide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | 11 |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Prednisolone | Prednisolone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.31 · 2 records | Abbott Laboratories | BREZTRI, ENSITE PRECISION | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error